The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients
| Autor: | Carol Kwok, Yi-Qian He, Ka Li Cheung, Ashley Cheng, Roselle Lee, Yuan-Yuan Lei, Winnie Yeo, Suzanne C. Ho |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
China Cancer Research medicine.medical_specialty Breast Neoplasms Logistic regression 03 medical and health sciences 0302 clinical medicine Breast cancer Asian People Risk Factors Surveys and Questionnaires Internal medicine Humans Medicine Longitudinal Studies Prospective Studies Stage (cooking) Longitudinal cohort Prospective cohort study SOY ISOFLAVONES business.industry Incidence Carcinoma Ductal Breast Cancer Odds ratio Middle Aged Prognosis medicine.disease Isoflavones Carcinoma Lobular 030104 developmental biology Oncology 030220 oncology & carcinogenesis Female Soybeans Menopause business Follow-Up Studies |
| Zdroj: | Breast Cancer Research and Treatment. 181:167-180 |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-020-05616-3 |
| Popis: | This study investigated the association between soy isoflavone intake and menopausal symptoms (MPS) among Chinese women with early stage breast cancer in a prospective cohort study. In an on-going prospective cohort study that involved 1462 Chinese women with early stage breast cancer, MPS were assessed at 18, 36 and 60 months after cancer diagnosis using the validated menopausal rating scale (MRS) questionnaire. Daily soy food intake for the previous 12 months was assessed at the same time using a validated food frequency questionnaire. The associations between MPS and soy isoflavone intake were evaluated in multivariable logistic regression analyses. The prevalence of MPS was almost the same during the first 60 months after cancer diagnosis, which were 64.5%, 65.2%, and 63.9% at 18, 36, and 60 months, respectively. Patients with MPS tended to be younger than those without MPS. The intake of soy isoflavones was not associated with the total score of MRS at 18-month follow-up [highest vs lowest tertile, odds ratio (OR) = 1.00, 95% CI 0.75–1.34]. Similarly, no significant association was noted at 36-month (OR = 1.25, 95% CI 0.92–1.69) and 60-month (OR = 1.21, 95% CI 0.84–1.74) follow-up. With regards to specific domain within MRS, the risk of symptoms presenting in somatic domain was higher among breast cancer patients who were in the highest tertile of soy isoflavone intake at 36 months post-diagnosis (OR = 1.44, 95% CI 1.07–1.94, P-trend = 0.02), compared with the lowest tertile, where a stronger significant association was noted among patients who were younger than 60 years (OR = 1.52, 95% CI 1.05–2.20, P-trend = 0.03) and pre-menopausal (OR = 3.81, 95% CI 1.85–8.11, P-trend |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink